Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial

Published:2023-08 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Simon Michael W.¹,Bataille Regine²,Caldwell Nicole S.³,Gessner Bradford D.⁴,Jodar Luis⁴,Lamberth Erik³,Peng Yahong⁵,Scott Daniel A.³,Lei Lanyu⁵,Giardina Peter C.⁵,Gruber William C.⁵,Jansen Kathrin U.⁵,Thompson Allison⁵,Watson Wendy³

Affiliation:

1. Department of Pediatrics, University of Kentucky, Lexington, KY, USA

2. Gentle Medicine Associates, Boynton Beach, FL, USA

3. Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA

4. Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA

5. Vaccine Research and Development, Pfizer Inc, New York, NY, USA

Funder

Pfizer Inc

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2245727

Reference23 articles.

1. Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques

2. Healthcare utilization and cost of pneumococcal disease in the United States

3. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

4. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15

5. Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM 197 protein]). Full Prescribing Information. Philadelphia PA: Pfizer Inc; 2017.